Is Remodulin a High Risk Drug? A Comprehensive Analysis of its Safety Profile
•
4 min read
While Remodulin is a vital treatment for pulmonary arterial hypertension (PAH), its continuous intravenous (IV) infusion is linked to a risk of fatal bloodstream infections (BSIs), which contributes to it being considered a high risk drug. Its use, therefore, requires careful patient monitoring and strict safety protocols to mitigate these significant dangers.
